Roivant Sciences Files 8-K for Other Events
Ticker: ROIV · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1635088
Sentiment: neutral
Topics: 8-K, SEC Filing, Corporate Update
TL;DR
Roivant Sciences filed an 8-K, standard update, no major news yet.
AI Summary
Roivant Sciences Ltd. filed an 8-K on April 2, 2024, to report other events and financial statements. The filing does not contain specific details about new events, financial figures, or material agreements, but serves as a notification of these items being filed.
Why It Matters
This 8-K filing indicates Roivant Sciences is providing updates on its corporate activities and financial reporting to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and financial statements, not indicating any immediate material changes or risks.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- April 2, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Roivant Sciences Ltd.?
The primary purpose of this 8-K filing is to report 'Other Events' and to include financial statements and exhibits, as indicated in the filing details.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 2, 2024.
What is Roivant Sciences Ltd.'s principal executive office address?
Roivant Sciences Ltd.'s principal executive offices are located at 7th Floor 50 Broadway London SW1H 0DB United Kingdom.
What is Roivant Sciences Ltd.'s Commission File Number?
Roivant Sciences Ltd.'s Commission File Number is 001-40782.
What is the Standard Industrial Classification (SIC) code for Roivant Sciences Ltd.?
The Standard Industrial Classification (SIC) code for Roivant Sciences Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 735 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-04-02 07:10:35
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
- $1.5 billion — ivant's board of directors for an up to $1.5 billion common share repurchase program, includ
- $648.4 million — o., Ltd. ("Sumitomo") for approximately $648.4 million . A copy of the press release is attach
- $9 — mitomo at a purchase price per share of $9.10, for an aggregate purchase price of
Filing Documents
- ef20025692_8k.htm (8-K) — 36KB
- ef20025692_ex99-1.htm (EX-99.1) — 29KB
- 0001140361-24-017141.txt ( ) — 208KB
- roiv-20240402.xsd (EX-101.SCH) — 4KB
- roiv-20240402_lab.xml (EX-101.LAB) — 21KB
- roiv-20240402_pre.xml (EX-101.PRE) — 16KB
- ef20025692_8k_htm.xml (XML) — 4KB
01
Item 8.01. Other Events. Data Release On April 2, 2024, Roivant Sciences Ltd. ("Roivant") issued a press release announcing positive NEPTUNE study results for brepocitinib in non-anterior non-infectious uveitis, as well as authorization by Roivant's board of directors for an up to $1.5 billion common share repurchase program, including the repurchase of all common shares held by Sumitomo Pharma Co., Ltd. ("Sumitomo") for approximately $648.4 million . A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference into this Item 8.01. As described in the press release, Roivant will host a conference call and webcast to discuss the NEPTUNE results and its share repurchase program at 8:00 a.m. EDT on April 2 , 2024. Share Repurchase Roivant's board of directors has authorized a common share repurchase program, allowing for repurchases of Roivant common shares in an aggregate amount of up to $1.5 billion (excluding fees and expenses). The repurchase program will be funded with available cash and cash equivalents on hand and does not have an expiration date. The timing and total amount of common shares to be repurchased will depend on several factors, including the market price of the company's common shares, general business, macroeconomic and market conditions and other investment opportunities. Under the repurchase program, purchases may be conducted through open market transactions, tender offers or privately negotiated transactions, including the use of trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Pursuant to the share repurchase program, on April 2 , 2024 Roivant entered into a share repurchase agreement with Sumitomo to repurchase all 71,251,083 common shares held by Sumitomo at a purchase price per share of $9.10, for an aggregate purchase price of approximately $648.4 million. The repurchase transaction with Sumitomo is expected to close on or about April 4, 2024. The share repurcha
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated April 2, 2024 104 Cover Page Interactive Data File (embedded with Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROIVANT SCIENCES LTD. By: /s/ Matt Maisak Name: Matt Maisak Title: Authorized Signatory Dated: April 2, 2024